Lurdes Gano
Overview
Explore the profile of Lurdes Gano including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
85
Citations
412
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cachatra V, Martins A, Oliveira M, Oliveira M, Gano L, Paulo A, et al.
Org Biomol Chem
. 2024 Dec;
PMID: 39641597
The computational study of the most relevant interactions of the nanomolar purine nucleoside BuChE selective inhibitor has shown that the benzyl group at position 2 and the purine acetamido group...
2.
Oliveira M, Campello M, Gano L, Raposinho P, Belchior A, Mendes E, et al.
ChemMedChem
. 2024 Sep;
19(24):e202400438.
PMID: 39302068
We herein describe the radiosynthesis of a I-labeled acridine orange derivative ([I]-C), acting as a G-quadruplex binder, and its biological evaluation in cervical cancer models, aiming to enlighten its potential...
3.
Cavaco M, Fraga P, Valle J, Silva R, Gano L, Correia J, et al.
Fluids Barriers CNS
. 2024 May;
21(1):45.
PMID: 38802930
Blood-brain barrier (BBB) peptide-shuttles (BBBpS) are able to translocate the BBB and reach the brain. Despite the importance of brain targeting in pharmacology, BBBpS are poorly characterized. Currently, their development...
4.
Cavaco M, Perez-Peinado C, Valle J, Silva R, Gano L, Correia J, et al.
Biomed Pharmacother
. 2024 Apr;
174:116573.
PMID: 38613996
Triple-negative breast cancer (TNBC) is an aggressive subtype characterized by the absence of commonly targeted receptors. Unspecific chemotherapy is currently the main therapeutic option, with poor results. Another major challenge...
5.
Palma E, Ichedef C, Fernandes C, Belchior A, Raposinho P, Gano L, et al.
Chemistry
. 2024 Feb;
30(22):e202400285.
PMID: 38386665
The main goal of this work was to elucidate the potential relevance of (radio)metal chelates of Tc and Re targeting G-quadruplex structures for the design of new tools for cancer...
6.
Andre A, Dias J, Aguiar S, Leonardo A, Nogueira S, Amaral J, et al.
Front Vet Sci
. 2023 Sep;
10:1236136.
PMID: 37711439
Introduction: Cancer is a major public health problem with over 19 million cases reported in 2020. Similarly to humans, dogs are also largely affected by cancer, with non-Hodgkin's lymphoma (NHL)...
7.
Andre A, Dias J, Aguiar S, Nogueira S, Bule P, Carvalho J, et al.
Sci Rep
. 2023 Mar;
13(1):4837.
PMID: 36964198
Antibody-drug conjugates (ADCs) are among the fastest-growing classes of therapeutics in oncology. Although ADCs are in the spotlight, they still present significant engineering challenges. Therefore, there is an urgent need...
8.
Silva F, Mendes C, DOnofrio A, Campello M, Marques F, Pinheiro T, et al.
Nanotheranostics
. 2023 Jan;
7(1):22-40.
PMID: 36593794
Over the last decades, gold nanoparticles (AuNPs) have proven to be remarkable tools for drug delivery and theranostic applications in cancer treatment. On the other hand, Pt(IV) prodrugs have been...
9.
DOnofrio A, Silva F, Gano L, Raposinho P, Fernandes C, Sikora A, et al.
Pharmaceutics
. 2022 Dec;
14(12).
PMID: 36559063
Several gastrin-releasing peptide receptor (GRPR) antagonists with improved in vivo behavior have been recently developed and tested in the clinic. However, despite the generally mild side effects of peptide receptor...
10.
Pinho J, Matias M, Marques V, Eleuterio C, Fernandes C, Gano L, et al.
Biomed Pharmacother
. 2022 Nov;
157:114021.
PMID: 36399831
The aggressiveness of melanoma and lack of effective therapies incite the discovery of novel strategies. Recently, a new dual acting hybrid molecule (HM), combining a triazene and a ʟ-tyrosine analogue,...